Vitrolife AB (CHIX:VITRS) Beginning Cash Position: kr886 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VITRS Vitrolife AB CHIX:VITRS
74 GF Score
Price kr86.38
GF Value kr145.13
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Beginning Cash Position?

Vitrolife AB CHIX:VITRS 74 Beginning Cash Position is kr886 Mil as of Jun. 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 74/100 and a GF Value™ of kr145.13 (Possible Value Trap). The stock has 6 warning signs investors should review.

Vitrolife AB's Beginning Cash Position for the quarter that ended in Jun. 2026 was kr886 Mil.

Vitrolife AB's quarterly Beginning Cash Position declined from Dec. 2025 (kr1,109 Mil) to Mar. 2026 (kr808 Mil) but then increased from Mar. 2026 (kr808 Mil) to Jun. 2026 (kr886 Mil).

Vitrolife AB's annual Beginning Cash Position increased from Dec. 2023 (kr578 Mil) to Dec. 2024 (kr862 Mil) and increased from Dec. 2024 (kr862 Mil) to Dec. 2025 (kr1,135 Mil).

Vitrolife AB Beginning Cash Position Related Terms

Vitrolife AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB Beginning Cash Position Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 973.00 629.00 578.00 862.00 1,135.00

Vitrolife AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,054.00 922.00 1,109.00 808.00 886.00
CHIX:VITRS
74GF Score
Vitrolife AB CHIX:VITRS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrolife AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr886 Mil mean?
Vitrolife AB (CHIX:VITRS) has a Beginning Cash Position of kr886 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Vitrolife AB and its competitors.
Is Vitrolife AB's Beginning Cash Position too high?
Vitrolife AB's current Beginning Cash Position is kr886 Mil. Overall, Vitrolife AB has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Beginning Cash Position compare to ABT and SYK?
Vitrolife AB's Beginning Cash Position of kr886 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current Beginning Cash Position is kr886 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr145.13, compared to a current price of kr86.38 — trading 40.5% below its estimated fair value. The current Beginning Cash Position is kr886 Mil. Vitrolife AB's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Beginning Cash Position is kr886 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr86.38 is trading 40.5% below its estimated GF Value™ of kr145.13. GuruFocus considers Vitrolife AB to be Possible Value Trap.

Key valuation signals for CHIX:VITRS:

  • Beginning Cash Position: kr886 Mil
  • GF Value™: kr145.13 vs. price of kr86.38 (40.5% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
74GF Score

Get the complete analysis for CHIX:VITRS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr86.38
Price
kr145.13
GF Value